Iovance Biotherapeutics(IOVA) - 2024 Q1 - Quarterly Results
Iovance Biotherapeutics(IOVA)2024-05-09 20:06Exhibit 99.1 Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates Strong Momentum for Amtagvi™ (Lifileucel) U.S. Launch Following U.S. Food and Drug Administration (FDA) Approval 100+ Amtagvi Patients Enrolled Across More Than 40 Current Authorized Treatment Centers (ATCs), with ~50 Total ATCs On Track by End of May and 70+ Total ATCs by Year-End 2024 Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive Officer of Iovance, stated, "The first quarter of 202 ...